Factors Associated With Treatment Failure in Moderately Severe Community-Acquired Pneumonia
Aurélien Dinh,Clara Duran,Jacques Ropers,Frédérique Bouchand,Benjamin Davido,Laurène Deconinck,Morgan Matt,Olivia Senard,Aurore Lagrange,Guillaume Mellon,Ruxandra Calin,Sabrina Makhloufi,Victoire de Lastours,Emmanuel Mathieu,Jean-Emmanuel Kahn,Elisabeth Rouveix,Julie Grenet,Jennifer Dumoulin,Thierry Chinet,Marion Pépin,Véronique Delcey,Sylvain Diamantis,Daniel Benhamou,Virginie Vitrat,Marie-Christine Dombret,Didier Guillemot,Bertrand Renaud,Yann-Erick Claessens,José Labarère,Philippe Aegerter,Jean-Pierre Bedos,Anne-Claude Crémieux,Julie ATTAL-BEHAR,Sébastien BEAUNE,Thierry CHINET,Tristan CUDENNEC,Marine DE LAROCHE,Albane DE THEZY,Jennifer DUMOULIN,Caroline DUPONT,Elise FERCOT,Violaine GIRAUT,Ségolène GREFFE,Julie GRENET,Caroline GUYOT,Jean-Emmanuel KAHN,Sylvie LABRUNE,Marie LACHATRE,Sophie MOULIAS,Charlotte NALINE,Marion PEPIN,Elisabeth ROUVEIX,Marine SAHUT-D'IZARN,Abel SEFSSAFI,Laurent TEILLET,Jean-Pierre BRU,Jacques GAILLAT,Vincent GAUTIER,Cécile JANSSEN,Leonardo PAGANI,Virginie VITRAT,Malika ABDERRAHMANE,Juliette CAMUSET,Catherine LEGALL,Pascale LONGUET-FLANDRES,Anne-Marie MENN,Victoire DE LASTOURS,Marie LECRONIER,Gwenolée PREVOST,Charles BURDET,Ouda DERRADJI,Lelia ESCAUT,Etienne HINGLAIS,Philippe LEBRAS,Edouard LEFEVRE,Mathilde NOAILLON,Pauline RABIER,Maurice RAPHAEL,Elina TEICHER,Christiane VERNY,Daniel VITTECOQ,Benjamin WYPLOSZ,Michèle BEN HAYOUN,Françoise BRUN-VEZINET,Enrique CASALINO,Christophe CHOQUET,Marie-Christine DOMBRET,Xavier DUVAL,Nadhira HOUHOU,Véronique JOLY,Xavier LESCURE,Manuela POGLIAGHI,Christophe RIOUX,Yazdan YAZDANPANAH,Elsa BARROS,Belinda BEGGA,Sébastien BOUKOBZA,Houria BOUREDJI,Imad CHOUAHI,Isabelle DELACROIX,Antoine FROISSART,Valérie GARRAIT,Elsa NGWEM,Catherine PHLIPPOTEAU,Sepehr SALEHABADI,Cécile TOPER,Florent VINAS,Marie AMSILLI,Olivier EPAULARD,Patricia PAVESE,Isabelle PIERRE,Jérôme AULAGNIER,Julie CELERIER,Roxana COJOCARIU,Emmanuel MATHIEU,Charlotte RACHLINE,Yoland SCHOINDRE,Thomas SENE,Christelle THIERRY,Caroline APARICIO,Véronique DELCEY,Amanda LOPES,Marjolaine MORGAND,Pierre SELLIER,Guy SIMONEAU,Catherine CHAKVETADZE,Sylvain DIAMANTIS,Arnaud GAUTHIER,Kaoutar JIDAR,Béatrice JOURDAIN,Jean-Francois BOITIAUX,Patrick DESCHAMPS,Edouard DEVAUD,Bruno PHILIPPE,Ruxandra-Oana CALIN,Tomasz CHROBOCZEK,Benjamin DAVIDO,Laurène DECONINCK,Pierre DE TRUCHIS,Aurore LAGRANGE,Sabrina MAKHLOUFI,Morgan MATT,Guillaume MELLON,Olivia SENARD,Daniel BENHAMOU,Claire CHAPUZET,Laure CHAUFFREY,Manuel ETIENNE,Luc-Marie JOLY,Bérengère OBSTOY,Mathieu SALAUN,Luc THIBERVILLE,Julie TILLON,Diane BOLLENS,Julie BOTTERO,Pauline CAMPA,Gäelle COSQUERIC,Bénédicte LEFEBVRE,Zineb OUAZENE,Jérôme PACANOWSKI,Dominique PATERON,Nadia VALIN,Caroline COMPAIN,Hugues CORDEL,Benoit DOUMENC,Elena FOIS,Nicolas GAMBIER,Marie-Aude KHUONG,Elisa PASQUALONI,Marie POUPARD,
DOI: https://doi.org/10.1001/jamanetworkopen.2021.29566
2021-10-15
JAMA Network Open
Abstract:Importance: Failure of treatment is the most serious complication in community-acquired pneumonia (CAP).Objective: To assess the potential risk factors for treatment failure in clinically stable patients with CAP.Design, Setting, and Participants: This secondary analysis assesses data from a randomized clinical trial on CAP (Pneumonia Short Treatment [PTC] trial) conducted from December 19, 2013, to February 1, 2018. Data analysis was performed from July 18, 2019, to February 15, 2020. Patients hospitalized at 1 of 16 centers in France for moderately severe CAP who were clinically stable at day 3 of antibiotic treatment were included in the PTC trial and analyzed in the per-protocol trial population.Interventions: Patients were randomly assigned (1:1) on day 3 of antibiotic treatment to receive β-lactam (amoxicillin-clavulanate [1 g/125 mg] 3 times daily) or placebo for 5 extra days.Main Outcomes and Measures: The main outcome was failure at 15 days after first antibiotic intake, defined as a temperature greater than 37.9 °C and/or absence of resolution or improvement of respiratory symptoms and/or additional antibiotic treatment for any cause. The association among demographic characteristics, baseline clinical and biological variables available (ie, at the first day of β-lactam treatment), and treatment failure at day 15 among the per-protocol trial population was assessed by univariate and multivariable logistic regressions.Results: Overall, 310 patients were included in the study; this secondary analysis comprised 291 patients (174 [59.8%] male; mean [SD] age, 69.6 [18.5] years). The failure rate was 26.8%. Male sex (odds ratio [OR], 1.74; 95% CI, 1.01-3.07), age per year (OR, 1.03; 95% CI, 1.01-1.05), Pneumonia Severe Index score (OR, 1.01; 95% CI, 1.00-1.02), the presence of chronic lung disease (OR, 1.85; 95% CI, 1.03-3.30), and creatinine clearance (OR, 0.99; 95% CI, 0.98-1.00) were significantly associated with failure in the univariate analysis. When the Pneumonia Severe Index score was excluded to avoid collinearity with age and sex in the regression model, only male sex (OR, 1.92; 95% CI, 1.08-3.49) and age (OR, 1.02; 95% CI, 1.00-1.05) were associated with failure in the multivariable analysis.Conclusions and Relevance: In this secondary analysis of a randomized clinical trial, among patients with CAP who reached clinical stability after 3 days of antibiotic treatment, only male sex and age were associated with higher risk of failure, independent of antibiotic treatment duration and biomarker levels. Another randomized clinical trial is needed to evaluate the impact of treatment duration in populations at higher risk for treatment failure.
medicine, general & internal